Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 125,000 shares of Opko Health stock in a transaction that occurred on Wednesday, May 22nd. The shares were purchased at an average price of $2.00 per share, with a total value of $250,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $6,137,902. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, May 16th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The shares were purchased at an average price of $2.02 per share, with a total value of $202,000.00.
  • On Monday, May 13th, Phillip Md Et Al Frost acquired 200,000 shares of Opko Health stock. The shares were purchased at an average price of $1.99 per share, with a total value of $398,000.00.
  • On Friday, May 10th, Phillip Md Et Al Frost acquired 70,000 shares of Opko Health stock. The shares were purchased at an average price of $2.08 per share, with a total value of $145,600.00.
  • On Wednesday, May 8th, Phillip Md Et Al Frost acquired 907,000 shares of Opko Health stock. The shares were purchased at an average price of $2.11 per share, with a total value of $1,913,770.00.
  • On Monday, April 22nd, Phillip Md Et Al Frost acquired 80,000 shares of Opko Health stock. The shares were purchased at an average price of $2.32 per share, with a total value of $185,600.00.
  • On Wednesday, April 17th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were purchased at an average price of $2.42 per share, with a total value of $121,000.00.
  • On Monday, April 15th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were bought at an average cost of $2.47 per share, with a total value of $24,700.00.
  • On Thursday, April 11th, Phillip Md Et Al Frost purchased 30,000 shares of Opko Health stock. The shares were bought at an average cost of $2.49 per share, with a total value of $74,700.00.
  • On Tuesday, April 9th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were bought at an average cost of $2.51 per share, with a total value of $25,100.00.
  • On Thursday, April 4th, Phillip Md Et Al Frost purchased 20,000 shares of Opko Health stock. The shares were bought at an average cost of $2.53 per share, with a total value of $50,600.00.

NASDAQ:OPK opened at $1.98 on Thursday. Opko Health Inc. has a 52-week low of $1.92 and a 52-week high of $6.40. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.10 and a quick ratio of 0.99. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -7.92 and a beta of 1.81.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.08). Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. The company had revenue of $222.50 million for the quarter, compared to the consensus estimate of $241.27 million. During the same period in the prior year, the firm posted ($0.08) EPS. The business’s revenue for the quarter was down 12.7% on a year-over-year basis. Equities research analysts predict that Opko Health Inc. will post -0.42 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its stake in shares of Opko Health by 40.8% in the fourth quarter. Rhumbline Advisers now owns 475,850 shares of the biotechnology company’s stock worth $1,432,000 after acquiring an additional 137,968 shares during the period. Paloma Partners Management Co bought a new position in Opko Health during the fourth quarter valued at approximately $319,000. Virtu Financial LLC bought a new position in Opko Health during the first quarter valued at approximately $173,000. Strs Ohio boosted its stake in Opko Health by 27.0% during the fourth quarter. Strs Ohio now owns 112,500 shares of the biotechnology company’s stock valued at $338,000 after buying an additional 23,900 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Opko Health by 36.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,049 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 6,097 shares during the last quarter. 22.73% of the stock is owned by hedge funds and other institutional investors.

Several analysts have issued reports on the company. ValuEngine lowered Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a report on Tuesday, April 30th. Finally, Barrington Research reissued a “buy” rating and set a $5.00 price target on shares of Opko Health in a report on Thursday, February 28th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Opko Health currently has an average rating of “Buy” and a consensus price target of $9.25.

ILLEGAL ACTIVITY WARNING: “Phillip Md Et Al Frost Acquires 125,000 Shares of Opko Health Inc. (OPK) Stock” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://theolympiareport.com/2019/05/23/phillip-md-et-al-frost-acquires-125000-shares-of-opko-health-inc-opk-stock.html.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

See Also: How To Calculate Debt-to-Equity Ratio

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.